Skip to main content
Top
Published in: Current Oncology Reports 3/2013

01-06-2013 | Palliative Medicine (A Jatoi, Section Editor)

Clearing the Air: A Review of Our Current Understanding of “Chemo Fog”

Authors: Erin O’Farrell, Joyce MacKenzie, Barbara Collins

Published in: Current Oncology Reports | Issue 3/2013

Login to get access

Abstract

An increasing number of cancer survivors has led to a greater interest in the long-term side effects of cancer treatments and their impact on quality of life. In particular, cognitive impairments have been frequently reported by cancer survivors as an adverse effect which they attribute to the neurotoxicity of chemotherapy and have dubbed “chemobrain” or “chemo fog.” Research within the past 15–20 years has explored the many factors thought to contribute to cancer-related cognitive decline in an attempt to determine a potential cause. In spite of many confounding factors, there is growing evidence that the neurotoxicity of chemotherapy does contribute to cognitive changes. This review examines the evolution of “chemo fog” research with a look at methodological issues, the status of our current understanding, and suggestions for future research.
Literature
1.
go back to reference Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:323–32.CrossRef Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:323–32.CrossRef
2.
go back to reference Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6.CrossRef Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6.CrossRef
3.
go back to reference van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.PubMedCrossRef van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.PubMedCrossRef
4.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
5.
go back to reference Maki P, Hogervorst E. HRT and cognitive decline. Best Pract Res Clin Endocrinol Metab. 2003;17:105–22.PubMedCrossRef Maki P, Hogervorst E. HRT and cognitive decline. Best Pract Res Clin Endocrinol Metab. 2003;17:105–22.PubMedCrossRef
6.
go back to reference Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2012;126:123–7.PubMedCrossRef Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2012;126:123–7.PubMedCrossRef
8.
go back to reference Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995–8.PubMedCrossRef Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995–8.PubMedCrossRef
9.
go back to reference Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.PubMedCrossRef Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.PubMedCrossRef
10.
go back to reference Collins B, MacKenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early-stage breast cancer patients: a prospective study. Psychooncology. 2009;18:811–21.PubMedCrossRef Collins B, MacKenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early-stage breast cancer patients: a prospective study. Psychooncology. 2009;18:811–21.PubMedCrossRef
11.
go back to reference Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage. 2004;21:364–71.PubMedCrossRef Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage. 2004;21:364–71.PubMedCrossRef
12.
go back to reference Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.PubMedCrossRef Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.PubMedCrossRef
13.
go back to reference Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–6.PubMedCrossRef Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–6.PubMedCrossRef
14.
go back to reference Palmer JL, Trotter T, Joy AA, et al. Cognitive effects of tamoxifen in premenopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2:275–82.PubMedCrossRef Palmer JL, Trotter T, Joy AA, et al. Cognitive effects of tamoxifen in premenopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2:275–82.PubMedCrossRef
15.
go back to reference Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in post-menopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011;126:221–6.PubMedCrossRef Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in post-menopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011;126:221–6.PubMedCrossRef
16.
go back to reference Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exesestance on cognitive functioning of post-menopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exesestance Adjuvant Multinational Trial. J Clin Oncol. 2010;28:1294–300.PubMedCrossRef Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exesestance on cognitive functioning of post-menopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exesestance Adjuvant Multinational Trial. J Clin Oncol. 2010;28:1294–300.PubMedCrossRef
17.
go back to reference Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12.PubMedCrossRef Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12.PubMedCrossRef
18.
go back to reference Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–9.PubMedCrossRef Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–9.PubMedCrossRef
19.
go back to reference • Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703–8. An international task force was formed to establish guidelines for research in the area of cognition and cancer. PubMedCrossRef • Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703–8. An international task force was formed to establish guidelines for research in the area of cognition and cancer. PubMedCrossRef
20.
go back to reference Cimprich B, Reuter-Lorenz P, Nelson J, et al. Pre-chemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32:324–31.PubMedCrossRef Cimprich B, Reuter-Lorenz P, Nelson J, et al. Pre-chemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32:324–31.PubMedCrossRef
21.
go back to reference Schilder CM, Seynaeve C, Linn SC, et al. The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology. 2010;19:415–22.PubMedCrossRef Schilder CM, Seynaeve C, Linn SC, et al. The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology. 2010;19:415–22.PubMedCrossRef
22.
go back to reference Wefel JS, Lenzi R, Theriault R, et al. “Chemobrain” in breast carcinoma?A prologue. Cancer. 2004;101:466–75.PubMedCrossRef Wefel JS, Lenzi R, Theriault R, et al. “Chemobrain” in breast carcinoma?A prologue. Cancer. 2004;101:466–75.PubMedCrossRef
23.
go back to reference Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17:122–30.PubMedCrossRef Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17:122–30.PubMedCrossRef
24.
go back to reference Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog – methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95:125–9.PubMedCrossRef Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog – methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95:125–9.PubMedCrossRef
25.
go back to reference Ouimet LA, Stewart A, Collins B, et al. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009;31:73–89.PubMedCrossRef Ouimet LA, Stewart A, Collins B, et al. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009;31:73–89.PubMedCrossRef
26.
go back to reference Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647–56.PubMedCrossRef Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647–56.PubMedCrossRef
27.
go back to reference Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21:485–92.CrossRef Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21:485–92.CrossRef
28.
go back to reference Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20:1361–75.PubMedCrossRef Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20:1361–75.PubMedCrossRef
29.
go back to reference Hutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38:926–34.PubMedCrossRef Hutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38:926–34.PubMedCrossRef
30.
go back to reference Pullens MJJ, DeVries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010;19:1127–38.PubMedCrossRef Pullens MJJ, DeVries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010;19:1127–38.PubMedCrossRef
31.
go back to reference Iconomou G, Mega V, Koutras A, et al. Prospective assessment of emotional distress, cognitive function and quality of life in patients with cancer treated with chemotherapy. J Cancer. 2004;101:404–11.CrossRef Iconomou G, Mega V, Koutras A, et al. Prospective assessment of emotional distress, cognitive function and quality of life in patients with cancer treated with chemotherapy. J Cancer. 2004;101:404–11.CrossRef
32.
go back to reference Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120–4.CrossRef Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120–4.CrossRef
33.
go back to reference Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267–75.PubMedCrossRef Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267–75.PubMedCrossRef
35.
go back to reference Scherling C, Collins B, MacKenzie J, et al. Pre-chemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34:543–60.PubMedCrossRef Scherling C, Collins B, MacKenzie J, et al. Pre-chemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34:543–60.PubMedCrossRef
36.
go back to reference Scherling C, Collins B, MacKenzie J, et al. Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy. Int J Biol. 2012;4:3–25. Scherling C, Collins B, MacKenzie J, et al. Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy. Int J Biol. 2012;4:3–25.
38.
go back to reference •• Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81. This longitudinal study examined the relationship between changes in neuropsychological functioning and brain structure following chemotherapy and found significant correlations between these two measures. PubMedCrossRef •• Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81. This longitudinal study examined the relationship between changes in neuropsychological functioning and brain structure following chemotherapy and found significant correlations between these two measures. PubMedCrossRef
39.
go back to reference Ganz PA. Doctor, will the treatment you are recommending cause chemobrain? J Clin Oncol. 2012;30:229–31.PubMedCrossRef Ganz PA. Doctor, will the treatment you are recommending cause chemobrain? J Clin Oncol. 2012;30:229–31.PubMedCrossRef
40.
go back to reference •• Collins B, MacKenzie J, Tasca GA, et al. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology. 2012. doi:10.1002/pon.3163. This is a prospective longitudinal study of cognitive functioning after cumulative exposure to chemotherapy. Patients were assessed at the baseline and following each chemotherapy cycle. A linear decline in cognitive functioning was observed, supporting a dose–response relationship and suggesting that chemotherapy is a cause of cognitive disturbance. PubMed •• Collins B, MacKenzie J, Tasca GA, et al. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology. 2012. doi:10.​1002/​pon.​3163. This is a prospective longitudinal study of cognitive functioning after cumulative exposure to chemotherapy. Patients were assessed at the baseline and following each chemotherapy cycle. A linear decline in cognitive functioning was observed, supporting a dose–response relationship and suggesting that chemotherapy is a cause of cognitive disturbance. PubMed
41.
go back to reference Hedayati E, Alinaghizadeh H, Schedin A, et al. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs. 2012;16:315–22.PubMedCrossRef Hedayati E, Alinaghizadeh H, Schedin A, et al. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs. 2012;16:315–22.PubMedCrossRef
42.
go back to reference Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53–61. doi:10.1007/s10549-005-7093-3.PubMedCrossRef Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53–61. doi:10.​1007/​s10549-005-7093-3.PubMedCrossRef
43.
go back to reference Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159–65.PubMedCrossRef Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159–65.PubMedCrossRef
44.
go back to reference Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742–5. doi:10.1093/jnci/djj470.PubMedCrossRef Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742–5. doi:10.​1093/​jnci/​djj470.PubMedCrossRef
45.
46.
go back to reference Brown MS, Simon JH, Stemmer SM, et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Am J Neuroradiol. 1995;16:2013–20.PubMed Brown MS, Simon JH, Stemmer SM, et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Am J Neuroradiol. 1995;16:2013–20.PubMed
47.
go back to reference Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol. 1998;19:217–21.PubMed Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol. 1998;19:217–21.PubMed
48.
go back to reference Stemmer SM, Stears JC, Burton BS, et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol. 1994;15:1267–73.PubMed Stemmer SM, Stears JC, Burton BS, et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol. 1994;15:1267–73.PubMed
49.
go back to reference Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35:729–41.PubMedCrossRef Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35:729–41.PubMedCrossRef
50.
go back to reference Winocur G, Henkelman M, Wojtowicz JM, et al. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18:3112–21.PubMedCrossRef Winocur G, Henkelman M, Wojtowicz JM, et al. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18:3112–21.PubMedCrossRef
51.
go back to reference de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19. doi:10.1002/hbm.21102.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19. doi:10.​1002/​hbm.​21102.PubMedCrossRef
52.
go back to reference Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68:1447–53.PubMedCrossRef Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68:1447–53.PubMedCrossRef
53.
go back to reference Silverman DH, Dy CJ, Castellon SA, et al. Altered fronto-cortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.PubMedCrossRef Silverman DH, Dy CJ, Castellon SA, et al. Altered fronto-cortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.PubMedCrossRef
54.
go back to reference Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88–91.PubMedCrossRef Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88–91.PubMedCrossRef
55.
go back to reference de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83. doi:10.1002/hbm.21422.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83. doi:10.​1002/​hbm.​21422.PubMedCrossRef
56.
go back to reference Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32:480–93.PubMedCrossRef Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32:480–93.PubMedCrossRef
57.
go back to reference Ferguson RJ, McDonald BC, Saykin AJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866–70.PubMedCrossRef Ferguson RJ, McDonald BC, Saykin AJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866–70.PubMedCrossRef
58.
go back to reference Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146–56.PubMedCrossRef Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146–56.PubMedCrossRef
59.
go back to reference Koppelmans V, de Ruiter MB, van der Lijn F, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132:1099–106.PubMedCrossRef Koppelmans V, de Ruiter MB, van der Lijn F, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132:1099–106.PubMedCrossRef
60.
go back to reference •• McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28. This was the first controlled prospective MRI study in the field of CRCI. PubMedCrossRef •• McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28. This was the first controlled prospective MRI study in the field of CRCI. PubMedCrossRef
61.
go back to reference Lopez-Zunini RA, Scherling C, Wallis N, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 2012. doi:10.1007/s11682-012-9213-0. Lopez-Zunini RA, Scherling C, Wallis N, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 2012. doi:10.​1007/​s11682-012-9213-0.
62.
go back to reference Jansen CE, Dodd MJ, Miaskowski CA, et al. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17:1189–95. doi:10.1002/pon.1342.PubMedCrossRef Jansen CE, Dodd MJ, Miaskowski CA, et al. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17:1189–95. doi:10.​1002/​pon.​1342.PubMedCrossRef
63.
66.
go back to reference Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25–34.PubMedCrossRef Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25–34.PubMedCrossRef
68.
go back to reference Jansen CE, Miaskowski C, Dodd M, et al. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33.PubMedCrossRef Jansen CE, Miaskowski C, Dodd M, et al. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33.PubMedCrossRef
69.
go back to reference Jansen CE, Miaskowski CA, Dodd MJ, et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairments in patients with breast cancer. Oncol Nurs Forum. 2007;34:997–1005.PubMedCrossRef Jansen CE, Miaskowski CA, Dodd MJ, et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairments in patients with breast cancer. Oncol Nurs Forum. 2007;34:997–1005.PubMedCrossRef
70.
go back to reference • Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87. This is a meta-analysis of 17 studies examining the long-term effects of chemotherapy on cognitive functioning. The results indicate cognitive deficits of small effect size in patients treated with chemotherapy as compared with healthy controls and patients not treated with chemotherapy. PubMedCrossRef • Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87. This is a meta-analysis of 17 studies examining the long-term effects of chemotherapy on cognitive functioning. The results indicate cognitive deficits of small effect size in patients treated with chemotherapy as compared with healthy controls and patients not treated with chemotherapy. PubMedCrossRef
71.
go back to reference Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychoogical effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.PubMedCrossRef Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychoogical effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.PubMedCrossRef
72.
go back to reference Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82.PubMedCrossRef Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82.PubMedCrossRef
73.
go back to reference Kopplemans V, Breteler MMB, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–6.CrossRef Kopplemans V, Breteler MMB, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–6.CrossRef
74.
go back to reference Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer. 2006;7:67–78.PubMedCrossRef Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer. 2006;7:67–78.PubMedCrossRef
75.
go back to reference Kreukels BPC, van Dam FSAM, Ridderinkhof KR, et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8:80–7.PubMedCrossRef Kreukels BPC, van Dam FSAM, Ridderinkhof KR, et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8:80–7.PubMedCrossRef
76.
go back to reference Kreukels BPC, Hamburger HL, de Ruiter MB, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol. 2008;119:533–41.PubMedCrossRef Kreukels BPC, Hamburger HL, de Ruiter MB, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol. 2008;119:533–41.PubMedCrossRef
77.
go back to reference Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18:134–43.PubMedCrossRef Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18:134–43.PubMedCrossRef
78.
go back to reference Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: subjective complaints and objective neuropsychological test results. Psychooncology. 2009;18:775–82. doi:10.1002/pon.1472.PubMedCrossRef Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: subjective complaints and objective neuropsychological test results. Psychooncology. 2009;18:775–82. doi:10.​1002/​pon.​1472.PubMedCrossRef
80.
go back to reference Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97:854–6.PubMedCrossRef Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97:854–6.PubMedCrossRef
81.
go back to reference Heck JE, Albert SM, Franco R, et al. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc. 2008;56:1687–92.PubMedCrossRef Heck JE, Albert SM, Franco R, et al. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc. 2008;56:1687–92.PubMedCrossRef
82.
go back to reference Baxter NN, Durham SB, Phillips KA, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;57:403–11.PubMedCrossRef Baxter NN, Durham SB, Phillips KA, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;57:403–11.PubMedCrossRef
83.
go back to reference Du XL, Xia R, Hardy D. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer. Am J Clin Oncol. 2010;33:533–43.PubMedCrossRef Du XL, Xia R, Hardy D. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer. Am J Clin Oncol. 2010;33:533–43.PubMedCrossRef
84.
go back to reference Mols F, Thong MSY, Vreugdenhil G, et al. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology. 2009;18:1252–60.PubMedCrossRef Mols F, Thong MSY, Vreugdenhil G, et al. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology. 2009;18:1252–60.PubMedCrossRef
85.
go back to reference Nieuwenhuijsen K, de Boer A, Spelten E, et al. The role of neuropsychological functioning in cancer survivors’ return to work one year after diagnosis. Psychooncology. 2009;18:589–97.PubMedCrossRef Nieuwenhuijsen K, de Boer A, Spelten E, et al. The role of neuropsychological functioning in cancer survivors’ return to work one year after diagnosis. Psychooncology. 2009;18:589–97.PubMedCrossRef
86.
go back to reference Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early post-treatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27:415–34.PubMedCrossRef Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early post-treatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27:415–34.PubMedCrossRef
87.
go back to reference Ahles TA, Saykin AJ, Noll WW, et al. The relationship of ApoE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef Ahles TA, Saykin AJ, Noll WW, et al. The relationship of ApoE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef
88.
go back to reference Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.PubMedCrossRef Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.PubMedCrossRef
89.
go back to reference Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97.PubMedCrossRef Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97.PubMedCrossRef
Metadata
Title
Clearing the Air: A Review of Our Current Understanding of “Chemo Fog”
Authors
Erin O’Farrell
Joyce MacKenzie
Barbara Collins
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 3/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-013-0307-7

Other articles of this Issue 3/2013

Current Oncology Reports 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine